Primate research center head will keep job despite misconduct, provoking shock and dismay
Deepak Kaushal will retain full duties despite falsifying and fabricating data in a monkey study
Related Articles
Plans to expand African vaccine production face steep hurdles
Moderna’s pause on Kenya project highlights difficulties in creating a competitive vaccine sector on the continent
Contribution of the patient microbiome to surgical site infection and antibiotic prophylaxis failure in spine surgery
Antibiotic-resistant bacteria that lead to surgical site infections in spine surgery originate from the preoperative patient microbiome.
US agency obstructs LGBTQ+ equity in science
The US National Center for Science and Engineering Statistics (NCSES) regularly conducts national surveys of the US-based PhD- and college-educated populations. These surveys monitor who…
Young toads are teaching Australian lizards to avoid deadly snacks
Massive trial shows monitor lizards will learn to avoid toxic and invasive adult toads after tasting less dangerous juveniles
Africa intensifies battle against mpox as ‘alarming’ outbreaks continue
New variant identified in Congolese mining town renews worries about global spread
Universities should experiment to improve caregiver support, U.S. National Academies says
New report recommends paid leave, flexible work policies, and changes in academic culture
Startups aim to curb climate change by pulling carbon dioxide from the ocean—not the air
Schemes to use renewable energy to process seawater may be cheaper and easier than air capture
Watch a beetle larva ambush snails from below, dragging them to their demise
Immature click beetles on the Ryukyu Islands of southwestern Japan display a behavior never before observed in their kind
A national-scale assessment of land subsidence in China’s major cities
China’s massive wave of urbanization may be threatened by land subsidence. Using a spaceborne synthetic aperture radar interferometry technique, we provided a systematic assessment of…
Messenger RNA technology shows first promise against a rare and deadly disease
“Milestone” Moderna trial finds fewer medical crises in some people with metabolic disorder after RNA infusions